If you have been reading about human growth hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
==== Ghana ==== In 2018, Zipline signed a contract with the government of Ghana to make up to 600 deliveries a day for four years at the cost of about $12.5 million. In April 2019, Ghana's president Nana Akufo-Addo announced the opening of the first distribution center in Ghana. Vice President Mahamudu Bawumia launched the first Zipline drone to Tafo Hospital on April 24, 2019. This first delivery contained a resupply shipment of yellow fever vaccines to prevent stock-out. In 2021, the government of Ghana expanded its contract with Zipline to add four additional distribution centers, bringing the total number of contracted distribution centers in the country to eight. Zipline presently operates six distribution centers in Ghana, serving over 2,300 health facilities. When the network is complete, Zipline will be able to serve about 85 percent of the population directly and the remainder indirectly, reaching over 3,200 health facilities in every region of the country. In March 2022, Zipline announced that the company had delivered over one million doses of the COVID-19 vaccine by drone in Ghana over the prior year. An independent study of Zipline's impact on the health system in Ghana found that Zipline's drone delivery service shortened vaccine stock-outs by 60 percent, decreased inventory-driven missed vaccination opportunities by 42 percent, decreased days facilities were without critical medical supplies by 21 percent, and increased the types of medicines and supplies stocked at health facilities by 10 percent.
Alumni of the Albert Einstein College of Medicine include seven elected members of the National Academy of Sciences, two Howard Hughes Medical Investigators, and five American Academy of Arts and Sciences members. Einstein graduate Charles S. Peskin, who developed mathematical models for blood flow in the heart and other biological fluids, was awarded a MacArthur "genius grant" in 1983. Alumnus Lucy Shapiro was awarded the National Medal of Science in 2011 and the Lasker–Koshland Special Achievement Award in Medical Science in 2025 for her work on bacterial genetics that helped found modern developmental biology. Scientific achievements by alumni include the co-discovery of the hepatitis C virus by George Kuo and the hormone leptin by Rudolph Leibel. Sankar Ghosh, currently a professor at Columbia University, conducted fundamental research on transcription factor NF-KB. Richard Bernstein developed blood glucose self-monitoring for diabetics. Raymond Vahan Damadian invented the nuclear magnetic resonance scanning machine and is credited by some with inventing magnetic resonance imaging (MRI) at large; for his MRI work Damadian was awarded the National Medal of Technology in 1988 and the Lemelson-MIT Program's Lifetime Achievement Award in 2001. Alumnus Ronald J. Ross first applied an MRI scanner in a clinical setting. Notable physicians include anesthesiologist Gary Hartstein, who served as the FIA Medical Delegate for the Formula One World Championship.
=== Manufacture === The development of the fluorocarbon industry coincided with World War II. Prior to that, fluorocarbons were prepared by reaction of fluorine with the hydrocarbon, i.e., direct fluorination. Because C-C bonds are readily cleaved by fluorine, direct fluorination mainly affords smaller perfluorocarbons, such as tetrafluoromethane, hexafluoroethane, and octafluoropropane.
The 5' terminus of the splint is designed to be complementary to the 3' end of the mRNA, and the 3' terminus of the splint is designed to be complementary to the 5' end of the DNA spacer linker, which usually consists of poly dA nucleotides (Figure 2).
Sources: en.wikipedia.org
=== Ulcerative colitis === Vedolizumab has been investigated in several studies in adult patients. Patients with moderate to severe active disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated received either vedolizumab or placebo. The main measure of effectiveness was the proportion of patients whose symptoms improved after six weeks of treatment. Vedolizumab was shown to be more effective than placebo: 47% (106 out of 225) of patients who received vedolizumab showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo. The study also showed that vedolizumab maintained the effect up to 52 weeks more effectively than placebo. Moreover, vedolizumab treatment was shown to achieve higher percentage of clinical remissions (31.3% vs. 22.5%) in patients with ulcerative colitis in comparison to adalimumab treatment.
=== Contact process === In 1831, British vinegar merchant Peregrine Phillips patented the contact process, which was a far more economical process for producing sulfur trioxide and concentrated sulfuric acid. Today, nearly all of the world's sulfuric acid is produced using this method. In the early to mid 19th century "vitriol" plants existed, among other places, in Prestonpans in Scotland, Shropshire and the Lagan Valley in County Antrim, Northern Ireland, where it was used as a bleach for linen. Early bleaching of linen was done using lactic acid from sour milk, but this was a slow process; the use of vitriol sped up the bleaching process.
==== Turfs ==== The term algal turf is commonly used but poorly defined. Algal turfs are thick, carpet-like beds of seaweed that retain sediment and compete with foundation species like corals and kelps, and they are usually less than 15 cm tall. Such a turf may consist of one or more species, and will generally cover an area in the order of a square metre or more. Some common characteristics are listed:
Sources: en.wikipedia.org
Induced expression of PGLYRP2 in keratinocytes is regulated by transcription factors NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and Sp1 (specificity protein 1) through sequences in the distal region of the promoter.
Aggregation of LDL cholesterol by ceramide causes LDL retention in arterial walls, leading to atherosclerosis. Ceramides cause endothelial dysfunction by activating protein phosphatase 2 (PP2A). In mitochondria, ceramide suppresses the electron transport chain and induces production of reactive oxygen species.
At the 1922 and 1923 elections, the Liberals won barely a third of the vote and only a quarter of the seats in the House of Commons as many radical voters abandoned the divided Liberals and went over to Labour. In 1922, Labour became the official opposition. A reunion of the two warring factions took place in 1923 when the new Conservative prime minister Stanley Baldwin committed his party to protective tariffs, causing the Liberals to reunite in support of free trade. The party gained ground in the 1923 general election but made most of its gains from Conservatives whilst losing ground to Labour—a sign of the party's direction for many years to come. The party remained the third largest in the House of Commons, but the Conservatives had lost their majority. There was much speculation and fear [by whom?] about the prospect of a Labour government and comparatively little about a Liberal government, even though it could have plausibly presented an experienced team of ministers compared to Labour's almost complete lack of experience as well as offering a middle ground that could obtain support from both Conservatives and Labour in crucial Commons divisions. However, instead of trying to force the opportunity to form a Liberal government, Asquith decided instead to allow Labour the chance of office in the belief that they would prove incompetent, and this would set the stage for a revival of Liberal fortunes at Labour's expense, but it was a fatal error.
=== Europe === A marketing authorisation application for 68Ga-PSMA-11 (INN Gallium (68Ga) gozetotide), under the brand name Illucix, was made to the Danish Medicines Agency, on behalf of several EU countries and the UK. Approval is expected in 2022. In 2022 a marketing authorisation application was made by the manufacturer of 18F-DCFPyL (branded Pylclari) to the European Medicines Agency. Polish manufacturer and distributor of radiopharmaceutical procuts, Polatom, has been granted a US patent for a 99mTc-PSMA-T4 kit. In the UK, Tc-99m labelled PSMA has product authorisation but lacks funding.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.